David Daniel

David Daniel

Auto-generated profile, based on publicly available information

David Daniel

Department of Pathology Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 April 2024 in Transfusion
Verified
Journal Article
Open access
DDDavid Daniel
David Daniel
KWKamille West‐Mitchell
Kamille West‐Mitchell

15 December 2020 in Frontiers in Education
Verified
Journal Article
Open access
PDF file
DCDonna Coch
Donna Coch
DDDavid B. Daniel
David B. Daniel
Lost in Translation: Educational Psychologists as Intermediaries Between Neuroscience and Education

9 October 2025 in Transfusion
Verified
Journal Article
Closed access
ECElizabeth P. Crowe
Elizabeth P. Crowe
COChinelo P. Onyenekwu
Chinelo P. Onyenekwu
JIJordan Ippolito
Jordan Ippolito
XFXinyi Feng
Xinyi Feng
HSHeather Smetana
Heather Smetana
EBEvan M. Bloch
Evan M. Bloch

1 April 2021 in Human Immunology
Verified
Journal Article
Open access
RMRachelle P. Mendoza
Rachelle P. Mendoza
WFWilliam Fyke
William Fyke
DDDavid Daniel
David Daniel
EGElmer Gabutan
Elmer Gabutan
BDBallabh Das
Ballabh Das
ANAllen J. Norin
Allen J. Norin
Early in the SARS-CoV-2 pandemic, convalescent plasma (CP) therapy was proposed as a treatment for severely ill patients. We conducted a CP treatment protocol under the Mayo Clinic Extended Access Program at University Hospital Brooklyn (UHB). Potential donors were screened with a lateral flow assay (LFA) for IgM and IgG antibodies against the SARS-CoV-2 S1 receptor-binding domain (RBD). Volunteers that were LFA positive were tested with an ELISA to measure IgG titers against the RBD. Subjects with titers of at least 1:1024 were selected to donate. Most donors with positive LFA had acceptable titers and were eligible to donate. Out of 171 volunteers, only 65 tested positive in the LFA (38.0%), and 55 (32.2%) had titers of at least 1:1024. Before our donation program started, 31 CP units were procured from the New York Blood Center (NYBC). Among the 31 CP units that were obtained from the NYBC, 25 units (80.6%) were positive in the LFA but only 12 units (38.7%) had titers of at least 1:1024. CP was administered to 28 hospitalized COVID-19 patients. Patients who received low titer CP, high titer CP and patients who did not receive CP were followed for 45 days after presentation. Severe adverse events were not associated with CP transfusion. Death was a less frequent outcome for patients that received high titer CP (>1:1024) 38.6% mortality, than patients that received low titer CP (≤1:1024) 77.8% mortality.

30 March 2026 in Vox Sanguinis
Verified
Journal Article
Open access
JJJeremy W. Jacobs
Jeremy W. Jacobs
NCNabajyoti Choudhury
Nabajyoti Choudhury
SASatyam Arora
Satyam Arora
AJAikaj Jindal
Aikaj Jindal
NBNidhi Bhatnagar
Nidhi Bhatnagar
EBEvan M. Bloch
Evan M. Bloch
Background and Objectives: Malaria still poses a public health burden in India despite ongoing elimination efforts. Blood donor screening for malaria is mandated in India, yet data on transfusion‐transmitted malaria (TTM) are lacking. We sought to evaluate testing practices for malaria, associated rates of positivity in donors and reported cases of TTM in India. Materials and Methods: We conducted a cross‐sectional survey of blood collection facilities in India from May to September 2025. Facilities were recruited through professional networks and direct outreach; responses were de‐identified. Data were collected on screening practices, malaria endemicity, quality control measures and TTM cases from 2020 to 2024. Results: Among 262 facilities, 256 (97.7%) reported routine malaria screening of all donations, most commonly using antigen rapid diagnostic tests (RDTs) (228/256, 89.1%). From 2020 to 2024, facilities tested 9,275,688 donations, with 1231 confirmed positive donations (overall 13.27 per 100,000 units) and a rising annual positivity rate from 3.4 to 22.0 per 100,000 units. Only eight facilities (3.1%) reported TTM cases, and less than half of facilities (116/256, 45.3%) participated in external quality assessment (EQA) and/or performed lookback investigations (88/262, 33.6%). Conclusion: In this national survey sample in India, almost all facilities reported routine malaria screening of blood donations, mostly using RDT. The findings suggest that rates of donor positivity may have increased, yet TTM is under‐recognized and/or unreported. Strengthening EQA and haemovigilance, particularly in malaria endemic regions, is needed to safeguard the blood supply, particularly as India strives towards malaria elimination.